Welcome to the Evana® healthcare professional training portal. The content in this portal has been developed to help pharmacists and their teams learn more about the new pharmacy medicines, Evana® Heavy Period Relief Tablets 500mg Tranexamic Acid for heavy menstrual bleeding, and Ultravana® Period Pain Relief Tablets 250mg Naproxen for period pain.
Select the product below to access our comprehensive training guides and case study content.
Evana Essential Information
Evana® Heavy Period Relief 500mg Tablets (Tranexamic acid) - PL 14251/0300. Indications: Reduction of heavy menstrual bleeding over several cycles in women with regular, 21-35 day cycles with no more than 3 day variation. Posology: Two tablets to be taken, 3 times a day at the onset of heavy menstrual bleeding, for a maximum of 4 consecutive days. Maximum daily dose of 8 tablets. Contraindications: Hypersensitivity to the active substance or any of the excipients, severe renal impairment, mild to moderate renal insufficiency, active thromboembolic disease, previous thromboembolic event and a family history of thrombophilia, haematuria, irregular menstrual bleeding, those taking warfarin, anticoagulants or oral contraceptives, pregnancy, fibrinolytic conditions following DIC, or history of convulsions. Precautions: Women aged over 45, those who are diabetic or obese, polycystic ovary syndrome, a family history of endometrial cancer, and those receiving unopposed oestrogen or tamoxifen, breastfeeding . Side effects: Common (≥1/100 to <1/10): Nausea, vomiting, diarrhoea. Uncommon (≥1/1,000 to <1/100): Allergic skin reactions. Very rare (<1/10,000): Hypersensitivity reactions including anaphylaxis. Frequency unknown: thromboembolic events, retinal/artery occlusion, impaired colour vision or visual disturbances, seizures. MA holder: Manx Healthcare Ltd, Taylor Group House, Wedgnock Lane, CV34 5YA, UK. Classification: P. RRP: 18 tablets: £14.95. Date: January 2024 – For full information see: evanaperiods.com/hcp/evana/spc.
Ultravana Essential Information
Ultravana® Period Pain Relief 250mg Gastro-resistant tablets (Naproxen) PL 20075/0619. Indication: Treatment of primary dysmenorrhoea in women aged 15-50 years. Posology: Day one: two tablets (500mg) to be taken, followed by one tablet (250mg) every 6-8 hours, if needed. Days 2 and 3: one tablet (250mg) to be taken every 6-8 hours. Maximum daily dose of 3 tablets (750mg), for a maximum of 3 days continuous use in any one cycle. Contraindications: hypersensitivity to the active substance or any of the excipients, patients with a history of, or active peptic ulcers and active gastrointestinal (GI) bleeding, history of GI bleeding or perforation related to previous NSAID therapy, aspirin or NSAID sensitivity, patients with severe heart, hepatic or renal failure, or those in the third trimester of pregnancy. Precautions: Not recommended in the elderly, in the first 6 months of pregnancy, when breast-feeding or in women attempting to conceive. Caution in patients with bronchial asthma or allergic disease, cardiac impairment, hypertension, impaired renal function, liver dysfunction, peripheral arterial or cerebrovascular disease, history of GI disease (e.g., ulcerative colitis, Crohn’s disease), coagulation disorders, and those taking oral corticosteroids, anticoagulants, antiplatelet agents, SSRIs or other NSAIDs. Contains lactose, not for patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. Side effects: Hypersensitivity reactions including non-specific allergic reactions and anaphylaxis, respiratory tract reactivity e.g., asthma, bronchospasm, dyspnoea, various skin reactions e.g., pruritus, urticaria, purpura, angioedema, bullous reactions including epidermal necrolysis, erythema multiforme, Stevens-Johnson Syndrome, DRESS. GI ulceration or haemorrhage, peptic ulceration, or perforation., hyperkalaemia, cardiac and congestive heart failure, myocardial infarction, stroke, renal failure, jaundice, hepatitis, meningitis. MA Holder: Accord Healthcare Limited, Sage House, 319 Pinner Road, HA1 4HF, UK. Classification: P. RRP: 9 tablets £5.95. Date: August 2024. For full information see the Ultravana SPC.